Nuno Lourenço-Silva, Ana Gimenez Arnau, Ivan Cherrez-Ojeda, Jean Bousquet, Jonathan A. Bernstein, Luis Felipe Ensina, Silvia Mariel Ferrucci, Michihiro Hide, Andreas Kleinheinz, Emek Kocatürk, Philip H. Li, Markus Magerl, Aiste Ramanauskaite, Krzysztof Rutkowski, Petra Staubach, Rafael José Vieira, Ellen Witte-Händel, Karsten Weller, Zuotao Zhao, Martin Metz, Sophia Neisinger, Bernardo Sousa Pinto
{"title":"Regional Patterns in the Prevalence of Patient-Reported Urticaria Aggravating Factors: A Multinational Mobile Health Study","authors":"Nuno Lourenço-Silva, Ana Gimenez Arnau, Ivan Cherrez-Ojeda, Jean Bousquet, Jonathan A. Bernstein, Luis Felipe Ensina, Silvia Mariel Ferrucci, Michihiro Hide, Andreas Kleinheinz, Emek Kocatürk, Philip H. Li, Markus Magerl, Aiste Ramanauskaite, Krzysztof Rutkowski, Petra Staubach, Rafael José Vieira, Ellen Witte-Händel, Karsten Weller, Zuotao Zhao, Martin Metz, Sophia Neisinger, Bernardo Sousa Pinto","doi":"10.1002/clt2.70220","DOIUrl":"https://doi.org/10.1002/clt2.70220","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In chronic spontaneous urticaria (CSU), exacerbations are often associated with aggravating factors. However, the prevalence of patients having aggravating factors has been insufficiently studied. This mHealth study aimed to (i) estimate the prevalence of patient-reported perceived aggravating factors for CSU across 10 countries, and (ii) identify factors associated with such triggers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed a cross-sectional analysis of data from users of the CRUSE mobile application. The study included patients aged 15–74 years with self-reported CSU. We assessed the frequency of reporting at least one of the following perceived aggravating factors: stress, food, exercise, low or high temperature, rubbing of the skin, infection, and medication. To correct for sample biases in age and sex distribution, we employed Multilevel Regression with Poststratification (MRP) models. In addition, we built logistic regression models to identify factors associated with perceived aggravating factor reporting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 12,243 included participants, 62.1% reported at least one perceived aggravating factor. Stress (31.1%) and rubbing of the skin (23.1%) were the most common. After MRP, the frequency of reporting at least one perceived aggravating factor ranged between 39.6% (Japan) and 83.7% (Brazil). The reporting frequency was lower in Asian than in Western countries. Female sex was independently associated with higher odds of reporting most perceived aggravating factors, except exercise and food. Younger age and lower disease control were associated with higher aggravating factor reporting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Patient-reported perceived aggravating factors varied substantially across countries. Female sex, younger age, and poorer disease control were associated with increased reporting. Cross-country differences may reflect biological, healthcare-related, cultural, and psychosocial influences.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 11","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70220","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149367531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jean Bousquet, Ludger Klimek, Hans-Christian Kuhl, Duc Tung Nguyen, Rajesh Kumar, William E. Berger
{"title":"Onset of Action of Azelastine 0.15% Versus Olopatadine/Mometasone for Allergen-Induced Rhinitis: An EEU Crossover Study","authors":"Jean Bousquet, Ludger Klimek, Hans-Christian Kuhl, Duc Tung Nguyen, Rajesh Kumar, William E. Berger","doi":"10.1002/clt2.70213","DOIUrl":"https://doi.org/10.1002/clt2.70213","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The aim of this study was to compare the onset of action (primary), and overall efficacy (secondary) of azelastine nasal spray 0.15% (AZE 0.15%) with mometasone/olopatadine combination therapy (OloMom) in subjects with allergen-induced rhinitis under controlled allergen exposure conditions in an Environmental Exposure Unit (EEU).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>This was a randomized, double-blind, placebo-controlled, three-period Williams cross-over study. Participants were randomized to receive AZE 0.15%, OloMom, or placebo. Efficacy was assessed during two pollen challenge sections in an EEC, after a single dose and after 3.5 days of treatment. Following a minimum 14-day washout period, subjects received alternate treatment and repeated study procedures until all three interventions were evaluated. The primary endpoint was time to onset of action based on change from baseline in Total Nasal Symptom Score (TNSS). Secondary assessments included total and individual nasal and ocular symptoms and overall efficacy after 3.5 days of treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eighty-four subjects completed the study (mean age 41.5 years; balanced sex distribution), all with confirmed ragweed sensitivity. All treatments reduced TNSS post-dose, with most effective and fastest relief from AZE 0.15%, onset at 15 minutes, sensitivity analyses supported onset at 10 minutes, and greater early nasal, ocular, and total symptom relief compared to OloMom and placebo.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>AZE 0.15% delivered rapid and clinically significant relief of AR, demonstrating greater early symptoms improvement compared with OloMom. Overall efficacy was comparable between treatments, supporting AZE 0.15% as an effective, steroid-free alternative for rapid symptom control in patients with pollen allergies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 11","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70213","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149367530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Time-of-Day Variation in Airway Hyperresponsiveness in Asthma: Potential Circadian Mechanisms and Translational Implications","authors":"Chang Zhou, Xinyue Hu, Lijuan Zeng, Yi Tang, Chuxian Yi, Guomin Zhang, Sujuan Peng","doi":"10.1002/clt2.70221","DOIUrl":"https://doi.org/10.1002/clt2.70221","url":null,"abstract":"<p>Airway hyperresponsiveness (AHR) is a key physiological feature of asthma and contributes to excessive airway narrowing in response to diverse stimuli. Although asthma-related airway physiology exhibits marked temporal variation, whether AHR itself is independently regulated by the endogenous circadian clock remains unclear. In this narrative review, we summarize current evidence on the definition and temporal phenotype of AHR, with particular emphasis on distinguishing clock-time variation from endogenous circadian regulation and on direct evidence from bronchial provocation studies. We further discuss potential mechanisms linking circadian biology to AHR, including neuroendocrine and autonomic gating, epithelial–immune temporal coupling, airway smooth muscle reactivity, and metabolic and redox regulation. Current evidence supports substantial time dependence of asthma-related airway physiology, whereas direct evidence for an intrinsic circadian rhythm of AHR in humans remains limited with mechanistic insights derived predominantly from animal, ex vivo, and cellular studies. We also review time-dependent treatment strategies, particularly inhaled corticosteroid (ICS) administration, while distinguishing clinically investigated dosing schedules from experimental clock-targeted interventions. Overall, circadian biology provides a framework for understanding temporal variation in AHR and may inform future approaches to phenotyping and treatment timing; however, circadian-based AHR management and clock-targeted therapies remain investigational and require validation in well-controlled human studies.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 11","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70221","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149367486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Giorgio Ciprandi, Amelia Licari, Cristiana Indolfi, Sara Manti, Michele Miraglia del Giudice, Maria Angela Tosca, Anna Maria Zicari, Gianluigi Marseglia
{"title":"A Current Evidence Review From the Italian Society of Pediatric Allergology and Immunology (SIAIP) on Practical Management of Allergic Rhinitis in Children and Adolescents","authors":"Giorgio Ciprandi, Amelia Licari, Cristiana Indolfi, Sara Manti, Michele Miraglia del Giudice, Maria Angela Tosca, Anna Maria Zicari, Gianluigi Marseglia","doi":"10.1002/clt2.70218","DOIUrl":"https://doi.org/10.1002/clt2.70218","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Allergic rhinitis (AR) is highly prevalent in children and adolescents and impairs quality of life, sleep, and school performance, while also worsening asthma control. The last EAACI position paper on pediatric AR was published in 2013. Significant scientific advancements, including the new ARIA 2026 guidelines, necessitate an updated national framework.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This Italian Society of Pediatric Allergology and Immunology (SIAIP) document aims to provide an evidence-based age-specific framework for the diagnosis, classification, and practical management of AR in children and adolescents, while addressing the limitations of existing less granular guidelines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A dedicated SIAIP experts' board reviewed current scientific literature, integrated updated epidemiological data, revised classifications, and emerging evidence on allergen immunotherapy. It incorporates the ARIA 2026 guidelines and adapts them to the clinical challenges and age-specific considerations relevant to pediatric practice. The board of qualified experts and a panel of multidisciplinary clinicians discussed and approved the document.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This document covers the epidemiology, pathophysiology, and diagnosis of AR in children and adolescents. It provides detailed stepwise pharmacologic recommendations and discusses the role of allergen immunotherapy (AIT), taking age-specific factors and complementary therapies into account. Evidence-based statements and practical management algorithms aim to optimize diagnostic pathways and therapeutic interventions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This SIAIP document offers clinically actionable guidance for healthcare professionals. It emphasizes early diagnosis, stepwise treatment strategies, and the disease-modifying role of AIT, aiming to enhance diagnostic accuracy, streamline management, and ultimately improve the long-term health and well-being of affected children and adolescents.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 11","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70218","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149367487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maren Poulsgaard Jørgensen, Andreas Kiesbye Øvlisen, Jonas Faartoft Jensen, Helene Bjørg Kristensen, Tarec Christoffer El-Galaly, Hanne Vestergaard, Sigurd Broesby-Olsen, Marianne Tang Severinsen
{"title":"Elevated Risk of Psychotropic Drug Prescriptions in Adults With Mastocytosis: A Danish Matched Cohort Study.","authors":"Maren Poulsgaard Jørgensen, Andreas Kiesbye Øvlisen, Jonas Faartoft Jensen, Helene Bjørg Kristensen, Tarec Christoffer El-Galaly, Hanne Vestergaard, Sigurd Broesby-Olsen, Marianne Tang Severinsen","doi":"10.1002/clt2.70223","DOIUrl":"https://doi.org/10.1002/clt2.70223","url":null,"abstract":"<p><strong>Background: </strong>Mastocytosis is a clonal mast cell disorder characterized by chronic mediator-related symptoms and heterogeneous systemic involvement. Neuropsychiatric symptoms are frequently reported, yet population-based evidence on incident depression and/or anxiety remains limited.</p><p><strong>Objective: </strong>To examine the mental health burden among patients with mastocytosis.</p><p><strong>Methods: </strong>We conducted a population-based matched cohort study using Danish health registers to evaluate incident, pharmacologically treated depression/anxiety among adult patients diagnosed with mastocytosis between 2005 and 2023. Patients were matched 1:5 with individuals from the general Danish population on age, sex, Charlson Comorbidity Index, and educational level. Individuals with psychotropic drug (PD) prescription within 10 years prior to index were excluded. Cumulative risks were estimated using the Aalen-Johansen estimator, and hazard ratios (HRs) were calculated using Cox proportional hazard regression.</p><p><strong>Results: </strong>We included 874 patients with mastocytosis and 4370 comparators. Patients had a higher risk of incident PD prescription in the 10 years following diagnosis (p < 0.001). The 5-year cumulative risk was 13.1% in patients and 8.4% in comparators. The HR for incident PD use was 1.72 (95% confidence interval 1.38-2.15, p < 0.001). Results were consistent across sensitivity and landmark analyses. Higher age, comorbidity, and shorter education were associated with increased risk.</p><p><strong>Conclusion: </strong>Mastocytosis was associated with an increased risk of PD prescriptions, possibly reflecting an increased burden of pharmacologically treated depression and/or anxiety, implying the importance of mental health awareness in clinical management.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 11","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149417183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Is It Safe to Reduce Inhaled Corticosteroid Dose in Severe Asthma Patients Receiving Biologic Therapy?","authors":"Nagihan Orhan Özer, Betül Özdel Öztürk, Begüm Görgülü Akın, Ceren Kaplankıran, Şadan Soyyiğit","doi":"10.1002/clt2.70204","DOIUrl":"https://doi.org/10.1002/clt2.70204","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Biologic therapies can control severe asthma and may modify its natural history beyond symptom control. However, step-down is not standardized, and its safety has not been clearly established.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This single-center retrospective cohort study reviewed adults with severe asthma on biologics (January 2019–May 2024). Step-down strategies (discontinuation of add-on therapy and/or inhaled corticosteroid [ICS] dose reduction) were described, success rates calculated, and clinical characteristics compared between groups with and without step-down.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Fifty-one patients were included, of whom 10 (19.6%) received omalizumab, 34 (66.7%) mepolizumab, and 7 (13.7%) benralizumab. After excluding 6 patients unsuitable for step-down assessment, 45 patients were compared. Step-down was attempted in 21 of these (46.7%) and succeeded in 17 (81.0%), defined as no systemic corticosteroid use, emergency visit, loss of control (ACT < 20), or exacerbation through the last visit. The most frequent interventions were ICS dose reduction (<i>n</i> = 7, 33.3%) and montelukast discontinuation (<i>n</i> = 7, 33.3%). Biologics had been received for a mean of 42.6 ± 14.0 months, and the reduced regimen was maintained for 8.15 ± 5.23 months. Compared with the non–step-down group, the step-down group had a higher proportion of males (<i>p</i> = 0.005) and longer follow-up (<i>p</i> = 0.007).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In this real-world cohort, step-down was feasible and appeared safe, with most patients maintaining the reduced regimen without deterioration in control or exacerbations. These findings support supervised treatment minimization in carefully selected, well-controlled patients, adding real-world evidence to a limited literature.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 10","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70204","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149258641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Treatment Choice and Cardiovascular Risk in Chronic Spontaneous Urticaria","authors":"Ralf J. Ludwig, Diamant Thaçi, Philip Curman","doi":"10.1002/clt2.70219","DOIUrl":"10.1002/clt2.70219","url":null,"abstract":"<p>To the Editor,</p><p>Chronic spontaneous urticaria (CSU) is increasingly recognized as a systemic inflammatory disease [<span>1</span>], including elevated risks for cardiovascular diseases (CVD) compared with the general population, with adjusted hazard ratios of 1.25–1.86 across six cardiovascular outcomes, including major adverse cardiovascular events [<span>2, 3</span>], yet the impact of treatment choice on CVD has not been addressed in CSU. Given the central role of inflammation in CSU pathobiology and cardiovascular disease (CVD), it is biologically plausible that effective disease control could mitigate CVD risk.</p><p>To address this, we used the US Collaborative Network of TriNetX, and performed a retrospective matched cohort study [<span>4</span>] comparing CSU treated with second-generation antihistamines (sgAH), omalizumab (OMA), or oral corticosteroids (oCS). Three pairwise matched analyses were conducted: OMA versus sgAH, OMA versus oCS, and sgAH versus oCS. Adults were included if they had ≥ 2 urticaria codes ≥ 6 weeks apart and received the treatment of interest in conjunction with an urticaria diagnosis. Two treatments (OMA, oCS) were reciprocally excluded from index up to 3 years thereafter. Second-generation antihistamines were not treated as an exclusion criterion, reflecting their guideline-recommended continuation alongside omalizumab; comparisons therefore contrast treatment strategies as applied in practice rather than mutually exclusive exposures. For each comparison, treatment cohorts were matched 1:1 using propensity-score covariates (Supporting Information S1: Table S1) and identical follow-up windows were applied to ensure comparability. Three predefined analyses were performed: primary analysis (1 day–3 years), sensitivity analysis excluding the first 3 months (S1), and a mandatory follow-up requiring a healthcare visit between 1 and 3 years after index (S2) (Supporting Information S1: Figure S1).</p><p>Across comparisons, baseline characteristics were well-balanced after matching with cohort sizes of ∼3300 for OMA groups and ∼31,000 for sgAH/oCS (Table 1; Supporting Information S1: Table S1). The primary outcome was any CVD, defined as a composite of major cardiovascular diagnoses assessed using time-to-event Cox models. Secondary outcomes included major adverse cardiovascular events (MACE), venous thromboembolism (VTE), and other CVD (Supporting Information S1: Table S2). Any CVD showed a clear pattern across all analyses: OMA was consistently associated with lower CVD risk compared with both oCS and sgAH. Compared with oCS, OMA users had substantially lower absolute risk across all analysis windows (e.g., primary: 3.55% vs 8.06%; S1: 2.75% vs 6.81%; S2: 4.21% vs 9.22%), with adjusted hazard ratios (aHRs) ranging 0.51–0.54 (all <i>p</i> < 0.001) (Figure 1). Lower risk versus sgAH followed the same trend. Furthermore, sgAH demonstrated modestly lower CVD risk compared to oCS. These findings were directionally","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 10","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149237168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Merve Hormet Igde, Pelin Korkmaz, Semra Demir, Osman Ozan Yegit, Derya Ünal, Merve Dilşad Atasever, Ayşe Feyza Aslan, Leyla Bölek, Selin Ece Güzel, Nevzat Kahveci, Mehmet Emin Sezgin, Şule Çelik Kamacı, Esra Kaya, Bircan Erden, Asli Gelincik
{"title":"NSAID Tolerance Can Be Restored in NECD Even in the Absence of Complete Remission of Urticaria","authors":"Merve Hormet Igde, Pelin Korkmaz, Semra Demir, Osman Ozan Yegit, Derya Ünal, Merve Dilşad Atasever, Ayşe Feyza Aslan, Leyla Bölek, Selin Ece Güzel, Nevzat Kahveci, Mehmet Emin Sezgin, Şule Çelik Kamacı, Esra Kaya, Bircan Erden, Asli Gelincik","doi":"10.1002/clt2.70216","DOIUrl":"10.1002/clt2.70216","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background/Aim</h3>\u0000 \u0000 <p>Data on the course of nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity in NSAID-exacerbated cutaneous disease (NECD) are limited. We aimed to evaluate NSAID tolerance in NECD patients with well-controlled urticaria.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>142 patients with well-controlled urticaria [Urticaria Control Test (UCT) ≥ 12; Urticaria Activity Score over 7 days (UAS7) ≤ 6] underwent a single blind, placebo-controlled acetylsalicylic acid (ASA) provocation test. Patients were categorized into three groups based on their treatment; omalizumab, antihistamine, or no treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The median age of the patients was 40 years (IQR 31.5–52), and 79.6% were female. The median disease duration of chronic spontaneous urticaria (CSU) was 4 years (IQR 2–8). The ASA provocation test was positive in 29 patients (20.4%). Positive patients had lower UCT and higher UAS7 scores (both <i>p</i> < 0.001). ASA provocation test positivity was more common in the antihistamine group compared to both the omalizumab (<i>p</i> = 0.001) and untreated groups (<i>p</i> < 0.001). ROC analysis showed that UCT ≤ 15 predicted ASA provocation test positivity with 72.4% sensitivity and 83.2% specificity, while UAS7 ≥ 4 predicted positivity with 72.4% sensitivity and 86.7% specificity. The negative predictive values (NPV) were 92.2% and 92.5%, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>To our knowledge, this is the first study to demonstrate, in a large NECD cohort, that NSAID tolerance can be achieved in patients with well-controlled urticaria under different treatment modalities, regardless of complete remission status. UCT ≤ 15 and UAS7 ≥ 4 are useful clinical predictors of provocation test positivity and, given their high NPVs, are particularly valuable for excluding positivity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 10","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13687787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149237216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ju Chang-Chien, Tzu-Han Su, Xin-Hui Lin, Yu-Hsuan Liao, Yi-Fen Tsai, Yin Szu, Yen-Chieh Meng, Ming-Ling Kuo, Hui-Ju Tsai, Tsung-Chieh Yao
{"title":"Association of Mitochondrial DNA Copy Number With Atopic Dermatitis in Children","authors":"Ju Chang-Chien, Tzu-Han Su, Xin-Hui Lin, Yu-Hsuan Liao, Yi-Fen Tsai, Yin Szu, Yen-Chieh Meng, Ming-Ling Kuo, Hui-Ju Tsai, Tsung-Chieh Yao","doi":"10.1002/clt2.70214","DOIUrl":"10.1002/clt2.70214","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Mitochondrial DNA copy number (mtDNA-CN), a marker associated with mitochondrial function and cellular health, has been implicated in several chronic inflammatory diseases. Atopic dermatitis is a common chronic inflammatory skin disorder, yet the relationship between mtDNA-CN and childhood atopic dermatitis remains unclear. This study aimed to investigate the association between mtDNA-CN and atopic dermatitis in a population-based cohort of school-aged children.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We included 1329 singleton children (56.4% boys; mean age ± standard deviation: 6.5 ± 0.5 years) from the Longitudinal Investigation of Global Health in Taiwanese Schoolchildren (LIGHTS) cohort. Genomic DNA was extracted from peripheral blood, and mtDNA-CN was quantified by real-time quantitative polymerase chain reaction. Multivariable logistic regression models were applied.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 1329 children, 328 (24.7%) children had physician-diagnosed atopic dermatitis. Mean mtDNA-CN was lower in children with atopic dermatitis than in those without (289.62 ± 102.06 vs. 299.47 ± 91.90; <i>p</i> = 0.03). Each one-unit increase in log-transformed mtDNA-CN was associated with 28% lower odds of atopic dermatitis after adjustment for potential confounders (adjusted odds ratio: 0.72; 95% confidence interval: 0.54–0.96). Subgroup analyses showed that this inverse association was more pronounced among children breastfed for ≥ 3 months and those with a birth weight ≥ 2500 g.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study provides novel evidence of an inverse association between mtDNA-CN and atopic dermatitis in children. Further longitudinal and mechanistic studies are warranted to confirm these findings and to evaluate the potential utility of mtDNA-CN as a biomarker for atopic dermatitis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 10","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657800/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}